Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 45Genitourinary 6Gastrointestinal 3Endocrine 3Dermatologic 2Breast 2Sarcoma 1NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 3Prostatic Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 2Carboplatin 2taxane 1romidepsin 1repotrectinib 1pralsetinib 1liposomal doxorubicin 1atezolizumab 1Vinorelbine 1Temozolomide 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Oxaliplatin 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lactones 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Etoposide 1Drug Therapy 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × atezolizumab × NET × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡